Society for Immunotherapy of Cancer | Strategic Alliance Partners

September 24, 2016

Although checkpoint blockade inhibitors targeting the PD-1/PD-L1 pathway are currently dominating the oncology community's attention, there are many other exciting approaches to anticancer immunotherapy being explored in a range of solid tumors

September 21, 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses ongoing research related to immunotherapy in the field of melanoma. Sanger shared this insight during an interview with OncLive during the recent Society for Immunotherapy of Cancer Cancer Immunotherapy 101 meeting in New York City.

August 25, 2016

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

May 10, 2016

Antoni Ribas, MD, PhD, shares exciting clinical trial results of immunotherapy agents in patients with melanoma, as well as what the future holds for the field.